(Q58622887)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

title

Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

G L Davis

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

J R Beck

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

G Farrell

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 September 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

313-321

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

The long-term pathological evolution of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

Medical Assessment by a Delphi Group Opinion Technic

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

Foundations of Cost-Effectiveness Analysis for Health and Medical Practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

Prediction of response to interferon treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

Factors predictive of a beneficial response to therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00119.X

10.1046/J.1365-2893.1998.00119.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9795915%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference